histogen
announces
grant
award
department
defense
clinical
advancement
cartilage
regeneration
knee
investigational
new
drug
ind
filing
expected
fourth
quarter
san
diego
globe
newswire
histogen
nasdaq
hsto
therapeutics
company
focused
developing
potential
restorative
therapeutics
ignite
body
natural
process
repair
maintain
healthy
biological
function
awarded
million
grant
peer
reviewed
orthopedic
research
program
prorp
department
defense
dod
help
fund
phase
clinical
trial
regeneration
cartilage
knee
army
medical
research
acquisition
activity
chandler
street
fort
detrick
md
awarding
administering
acquisition
office
phase
clinical
trial
designed
evaluate
combination
microfracture
procedure
civilian
military
patients
recent
focal
cartilage
defects
knee
caused
injury
patients
enrolled
three
clinical
sites
oasismd
san
diego
ca
steadman
clinic
vail
co
walter
reed
medical
center
bethesda
md
addition
safety
parameters
endpoints
include
traditional
scores
pain
joint
function
knee
injury
osteoarthritis
outcome
scores
koos
international
knee
documentation
committee
ikdc
well
mri
quantify
cartilage
regeneration
steadman
clinic
world
renowned
dedication
excellence
treating
orthopedic
defects
excited
clinical
center
studying
histogen
human
extracellular
matrix
hecm
focal
lesions
knee
said
matthew
provencher
md
capt
mc
usnr
regenerating
uniform
functional
hyaline
cartilage
critical
restoring
normal
function
military
personnel
civilians
lesions
articular
knee
cartilage
cause
considerable
morbidity
current
surgical
options
may
result
uneven
repair
fibrous
cartilage
instead
normal
hyaline
cartilage
provides
greatest
function
said
gail
naughton
histogen
founder
cso
histogen
demonstrated
hyaline
cartilage
regeneration
three
different
vivo
animal
models
conducted
orthopedic
experts
honor
granted
award
dod
support
phase
trial
concluded
naughton
significant
need
improved
acute
knee
injury
treatments
military
civilian
populations
approximately
americans
affected
knee
cartilage
injuries
annually
requiring
surgical
interventioni
among
us
military
personnel
musculoskeletal
injuries
leading
cause
morbidity
lost
training
time
reduced
operational
readiness
resulting
many
million
health
visits
million
days
per
yearii
funds
support
efforts
clinically
evaluate
safety
efficacy
novel
cartilage
repair
treatment
applicability
military
civilian
populations
said
richard
pascoe
histogen
president
ceo
former
soldier
understand
health
readiness
servicemembers
essential
national
defense
pleased
partner
dod
prestigious
clinical
sites
advance
clinic
support
views
expressed
press
release
author
may
reflect
official
policy
position
department
army
department
defense
government
histogen
human
extracellular
matrix
hecm
intended
regenerating
hyaline
cartilage
treatment
articular
cartilage
defects
novel
malleable
scaffold
stimulates
body
stem
cells
multiple
preclinical
models
shown
regenerate
mature
cartilage
well
vascularized
bone
indicating
great
therapeutic
potential
sports
medicine
spinal
disc
repair
orthopedic
dental
areas
studies
conducted
outside
experts
demonstrated
angiogenic
stimulate
growth
stem
cells
damaged
areas
induce
tissue
regeneration
extensive
vivo
work
animals
focused
regeneration
new
hyaline
cartilage
bone
full
thickness
knee
injuries
histogen
histogen
therapeutics
company
focused
developing
potential
restorative
therapeutics
ignite
body
natural
process
repair
maintain
healthy
biological
function
histogen
innovative
technology
platform
utilizes
cell
conditioned
media
extracellular
matrix
materials
produced
multipotent
cells
histogen
proprietary
reproducible
manufacturing
process
provides
targeted
solutions
across
broad
range
therapeutic
indications
including
hair
growth
dermal
rejuvenation
joint
cartilage
regeneration
spinal
disk
repair
information
please
visit
statements
press
release
contains
statements
within
meaning
safe
harbor
provisions
private
securities
litigation
reform
act
federal
securities
laws
example
using
statements
discuss
histogen
future
operations
ability
successfully
initiate
complete
clinical
trials
achieve
regulatory
milestones
related
timing
including
related
planned
phase
clinical
trial
regeneration
cartilage
knee
nature
strategy
focus
histogen
business
development
commercial
potential
potential
benefits
histogen
product
candidates
histogen
may
actually
achieve
plans
carry
intentions
meet
expectations
projections
disclosed
statements
place
undue
reliance
statements
statements
deal
future
events
based
histogen
current
expectations
subject
various
risks
uncertainties
actual
results
performance
achievements
histogen
could
differ
materially
described
implied
statements
press
release
including
uncertainties
associated
clinical
development
regulatory
approval
histogen
product
candidates
including
potential
delays
commencement
enrollment
completion
clinical
trials
planned
phase
clinical
trial
regeneration
cartilage
knee
potential
earlier
clinical
trials
studies
histogen
product
candidates
may
predictive
future
results
risks
related
business
interruptions
including
outbreak
coronavirus
could
seriously
harm
histogen
financial
condition
increase
costs
expenses
requirement
additional
capital
continue
advance
product
candidates
may
available
favorable
terms
foregoing
review
important
factors
could
cause
actual
events
differ
expectations
construed
exhaustive
read
conjunction
statements
included
herein
elsewhere
including
risks
discussed
histogen
filings
securities
exchange
commission
except
otherwise
required
law
histogen
disclaims
intention
obligation
update
revise
statements
speak
date
hereof
whether
result
new
information
future
events
circumstances
otherwise
merkely
ackermann
j
lattermann
articular
cartilage
defects
incidence
diagnosis
natural
history
oper
tech
sports
med
ii
teyhen
goffar
shaffer
kiesel
butler
tedaldi
prye
rhon
plisky
j
incidence
musculoskeletal
injury
us
army
unit
types
prospective
cohort
study
orthop
sports
phys
ther
contact
